Your browser doesn't support javascript.
loading
21st Century Approaches for Evaluating Exposures, Biological Activity, and Risks of Complex Substances: Workshop highlights.
Sauer, Ursula G; Barter, Robert A; Becker, Richard A; Benfenati, Emilio; Berggren, Elisabet; Hubesch, Bruno; Hollnagel, Heli M; Inawaka, Kunifumi; Keene, Athena M; Mayer, Philipp; Plotzke, Kathleen; Skoglund, Robert; Albert, Océane.
Afiliación
  • Sauer UG; Scientific Consultancy - Animal Welfare, Neubiberg, Germany. Electronic address: ursula.sauer@sauerug.de.
  • Barter RA; ExxonMobil Biomedical Sciences, Inc., Annandale, NJ, USA.
  • Becker RA; American Chemistry Council, Washington DC, USA.
  • Benfenati E; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
  • Berggren E; European Commission, Joint Research Centre, Ispra, Italy.
  • Hubesch B; European Chemical Industry Council (Cefic), Brussels, Belgium; Hubesch Consult BVBA, Sint-Pieters-Leeuw, Belgium.
  • Hollnagel HM; Dow Europe GmbH, Horgen, Switzerland.
  • Inawaka K; Japan Chemical Industry Association, Tokyo, Japan.
  • Keene AM; Afton Chemical Corporation, Richmond, VA, USA.
  • Mayer P; Technical University of Denmark, Kongens Lyngby, Denmark.
  • Plotzke K; Dow, Midland, MI, USA.
  • Skoglund R; Covestro LLC, Pittsburgh, PA, USA.
  • Albert O; European Chemical Industry Council (Cefic), Brussels, Belgium.
Regul Toxicol Pharmacol ; 111: 104583, 2020 Mar.
Article en En | MEDLINE | ID: mdl-31935484
ABSTRACT
The June 2019 workshop 21st Century Approaches for Evaluating Exposures, Biological Activity, and Risks of Complex Substances, co-organised by the International Council of Chemical Association's Long-Range Research Initiative and the European Commission's Joint Research Centre, is summarised. Focus was the need for improved approaches to evaluate the safety of complex substances. Approximately 10% and 20% of substances registered under the EU chemicals legislation are 'multi-constituent substances' and 'substances of unknown or variable compositions, complex reaction products and biological substances' (UVCBs), respectively, and UVCBs comprise approximately 25% of the U.S. Toxic Substances Control Act Inventory. Workshop participants were asked to consider how the full promise of new approach methodologies (NAMs) could be brought to bear to evaluate complex substances. Sessions focused on using NAMs for screening, biological profiling, and in complex risk evaluations; improving read-across approaches employing new data streams; and methods to evaluate exposure and dosimetry. The workshop concluded with facilitated discussions to explore actionable steps forward. Given the diversity of complex substances, no single 'correct' approach was seen as workable. The path forward should focus on 'learning by doing' by developing and openly sharing NAM-based fit-for-purpose case examples for evaluating biological activity, exposures and risks of complex substances.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Pruebas de Toxicidad / Medición de Riesgo Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Animals / Humans Idioma: En Año: 2020 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Pruebas de Toxicidad / Medición de Riesgo Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Animals / Humans Idioma: En Año: 2020 Tipo del documento: Article